Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone978-671-8001
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$343.37 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Lantheus (NASDAQ:LNTH) Frequently Asked Questions
What is Lantheus' stock symbol?
Lantheus trades on the NASDAQ under the ticker symbol "LNTH."
How were Lantheus' earnings last quarter?
Lantheus Holdings Inc (NASDAQ:LNTH) released its quarterly earnings data on Tuesday, February, 19th. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.15 by $0.09. The medical equipment provider had revenue of $86.27 million for the quarter, compared to the consensus estimate of $83.93 million. Lantheus had a return on equity of 73.07% and a net margin of 11.80%. The company's revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.47 EPS. View Lantheus' Earnings History.
When is Lantheus' next earnings date?
What guidance has Lantheus issued on next quarter's earnings?
Lantheus issued an update on its FY19 earnings guidance on Tuesday, February, 19th. The company provided earnings per share (EPS) guidance of $1.14-1.17 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.96. The company issued revenue guidance of $358-363 million, compared to the consensus revenue estimate of $361.50 million.Lantheus also updated its FY 2019 guidance to $1.14-1.17 EPS.
What price target have analysts set for LNTH?
2 equities research analysts have issued 12 month price targets for Lantheus' shares. Their predictions range from $20.00 to $21.00. On average, they expect Lantheus' share price to reach $20.50 in the next year. This suggests that the stock has a possible downside of 13.2%. View Analyst Price Targets for Lantheus.
What is the consensus analysts' recommendation for Lantheus?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.
Has Lantheus been receiving favorable news coverage?
News coverage about LNTH stock has trended somewhat negative on Saturday, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Lantheus earned a coverage optimism score of -1.5 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Lantheus' key competitors?
Some companies that are related to Lantheus include Immunomedics (IMMU), Neogen (NEOG), Quidel (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Quotient (QTNT), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT) and ImmuCell (ICCC).
What other stocks do shareholders of Lantheus own?
Who are Lantheus' key executives?
Lantheus' management team includes the folowing people:
- Ms. Mary Anne Heino, CEO, Pres & Director (Age 59)
- Mr. Michael P. Duffy, Sr. VP of Law & Public Policy, Gen. Counsel and Sec. (Age 58)
- Mr. Robert J. Marshall Jr., CFO & Treasurer
- Mr. John J. Bolla, Sr. VP of Technical Operations & Director
- Ms. Meara Murphy, Director of Investor Relations & Corp. Communications
When did Lantheus IPO?
(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.
Who are Lantheus' major shareholders?
Lantheus' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.40%), LSV Asset Management (4.16%), Vaughan Nelson Investment Management L.P. (3.91%), Dimensional Fund Advisors LP (3.59%), Dimensional Fund Advisors LP (3.58%) and Tamarack Advisers LP (2.53%). Company insiders that own Lantheus stock include A Frederick Robertson, Avista Capital Partners Gp, Ll, Cesare Orlandi, David F Burgstahler, Derace L Schaffer, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy and Timothy G Healey. View Institutional Ownership Trends for Lantheus.
Which institutional investors are selling Lantheus stock?
LNTH stock was sold by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Eqis Capital Management Inc., BlackRock Inc., Prudential Financial Inc., Los Angeles Capital Management & Equity Research Inc., Barclays PLC, Natixis Advisors L.P. and Royce & Associates LP. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Cesare Orlandi, Julie Mchugh, Mary Anne Heino and Michael P Duffy. View Insider Buying and Selling for Lantheus.
Which institutional investors are buying Lantheus stock?
LNTH stock was purchased by a variety of institutional investors in the last quarter, including LSV Asset Management, Mesirow Financial Investment Management Equity Management, Peregrine Capital Management LLC, Raging Capital Management LLC, Vaughan Nelson Investment Management L.P., Millennium Management LLC, Citigroup Inc. and Dimensional Fund Advisors LP. View Insider Buying and Selling for Lantheus.
How do I buy shares of Lantheus?
Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lantheus' stock price today?
One share of LNTH stock can currently be purchased for approximately $23.62.
How big of a company is Lantheus?
Lantheus has a market capitalization of $910.55 million and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis.
What is Lantheus' official website?
How can I contact Lantheus?
Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]
MarketBeat Community Rating for Lantheus (NASDAQ LNTH)
MarketBeat's community ratings are surveys of what our community members think about Lantheus and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
